|
Background
A key barrier to CAR-T cell therapies for solid tumors is the immunosuppressive tumor microenvironment, where cytokines like TGF-β inhibit T cell proliferation, cytotoxicity, and persistence. TGF-β suppresses immune responses by activating Smad-dependent signaling pathways, leading to T cell anergy and exhaustion. Traditional approaches...
|